J.B.A.G. Haanen

LBA7 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study

Myriam Chalabi, Y.L. Verschoor, J. van den Berg et al. · Annals of Oncology · 2022 · 186 citations · Full text

Niche-2 Study, Cancer Immunosurveillance, Medicine +6

Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma

A. Ribas, Axel Hauschild, Richard Kefford et al. · Journal of Clinical Oncology · 2008 · 156 citations

Tremelimumab 15, Tremelimumab Arm, Immunology +18

Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Teresa Amaral, Margaret Ottaviano, Ana Arance et al. · Annals of Oncology · 2024 · 99 citations · Full text

Dermoscopic Image, Melanoma, Cutaneous Melanoma +3

Azathioprine-induced pure red-cell aplasia

J.B.A.G. Haanen, A. A. M. J. Hollander, G. J. den Ottolander · Nephrology Dialysis Transplantation · 1996 · 39 citations

Autoimmune Disease, Allergy, Apoptosis +5

A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma.

Steven O’Day, F. Stephen Hodi, David F. McDermott et al. · Journal of Clinical Oncology · 2010 · 32 citations

Immunology, Immunotherapeutics, Immunotherapy +16